Antibody Ingredients TRIZ Cases

Antibodies targeting TRAIL-R1 and TRAIL-R2 receptors induce apoptosis in cancer cells while sparing normal tissue to reduce hepatocyte toxicity.

Merging anti-progastrin binding molecules with immune checkpoint inhibitors overcomes single-agent resistance by elevating interferon gamma levels.

Merges curcumin derivatives with checkpoint inhibitor antibodies to suppress cancer cell proliferation where single-agent therapy fails.

Engineered human monoclonal antibodies resolve stability and cross-reactivity bottlenecks by optimizing variable domain sequences for enhanced binding affinity.

A bispecific antibody composition binds non-overlapping EGFR epitopes to stabilize the tethered receptor conformation.

Hybridoma-derived monoclonal antibodies resolve lot homogeneity issues and triglyceride interference in presepsin assays.

Anti-VISTA antibodies reverse tumor-mediated immune suppression by increasing neutrophils and macrophages in the tumor microenvironment.

A glycan-modified anti-CD4 antibody introduces an N-linked glycosylation site in the light chain variable region to enhance neutralization activity.

A humanized monoclonal antibody targets CD38 antigens on tumor cells to deliver direct cytotoxic effects.

Genetically modified tumor-specific T cells expand without IL-2 or GM-CSF support, eliminating toxicities while maintaining anti-tumor activity.

A humanized monoclonal antibody targets a specific conformational epitope on human GPVI to enable high-affinity binding.

Myxoma virus expressing multi-specific immune cell engagers selectively infects and kills cancer cells while sparing healthy tissue.

Anti-PD-1 monoclonal antibody featuring specific heavy chain variable region mutations that promote T cell activation and proliferation.

Anti-AGE antibodies selectively remove senescent cells, mitigating radiation-induced premature aging symptoms.

Proteolytic cleavage of masking moieties activates anti-PD1 antibodies locally, resolving systemic autoimmunity while enhancing anti-tumor activity.

Antibody 175 binds amplified wild-type and de2-7 EGFR variants via a unique conformational epitope, reducing uptake in normal tissues.

Antibodies targeting N113 and N145 glycosylation sites inhibit CTLA-4 interaction with CD80 and CD86, resolving specificity trade-offs in cancer therapy.

Novel humanized anti-BCMA antibodies enable targeted delivery of splicing modulators to malignancy cells.

Combining Hsp90 and HER2 inhibitors disrupts oncogenic signaling pathways to reduce tumor burden while maintaining safety profiles of individual agents.

Modifying amino acid sequences in complementarity determining regions enhances binding affinity while reducing immunogenic response.

MUC18-binding antibodies recognize glycosylated conformational epitopes on melanoma cells to inhibit tumor growth and metastasis.

Anti-OX40 antibodies activate immune cells to target cancer cells, resolving selectivity and resistance bottlenecks in solid tumor therapy.

Blocking the PD-1/PD-L1 interaction restores T cell activity against tumors, addressing limited effectiveness in advanced cancer stages.

Engineered monoclonal antibodies with pH-sensitive binding affinity reduce internalization and dosing frequency while sustaining tumor growth inhibition.

Isolated monoclonal antibodies target DDR1 receptors to inhibit tumor growth and enhance antitumor immune responses in breast cancer.

Novel CD137 antibodies bind human targets to enhance therapeutic efficacy.

Combining a humanized anti-CD4 antibody with immune checkpoint inhibitors reduces severe side effects from non-specific attacks on normal cells.

Engineered antibodies bind TIP1 to deliver drugs specifically to glioblastoma and lung cancer sites, reducing systemic toxicity.

Replacing PEG with a sugar alcohol and amino acid system prevents protein precipitation during freezing while maintaining storage stability.

Radionuclide-labeled anti-PD-L1 diabodies overcome heterogeneous tumor expression to provide accurate diagnostic assessment.

A bispecific antibody binds tumor-associated antigen GD2 and T cells to enable targeted cancer therapy.

Merging DGK and PD-1 inhibitors overcomes single-agent resistance to improve efficacy in MSI-H cancers.

Agonistic LILRB3 antibodies induce phenotypic changes in human myeloid cells to modulate immune responses.

Bispecific molecules targeting TRBC isoforms selectively deplete malignant T cells, resolving the trade-off between cancer elimination and immunosuppression.

Antibodies targeting ferroportin 1 prevent hepcidin-induced internalization, elevating serum iron levels without disrupting cellular efflux.

Merging anti-KIR and anti-CS1 antibodies overcomes treatment inefficacy by synergistically activating NK cells against multiple myeloma.

Engineered human antibodies with specific CDR sequences inhibit CXCR2 activation, reducing neutrophil infiltration without depleting circulating counts.

Protease-cleavable masking moiety blocks antibody binding to prevent off-target toxicities while extending circulation half-life.

Multispecific antibodies merge anti-PD-L1 and anti-B7-H3 binding to overcome limited affinity of single agents.

Inhibiting signal peptide peptidase sensitizes tumors to overcome checkpoint blockade limitations.

Merging EP4 antagonism with checkpoint inhibition converts immune suppression into enhanced anti-tumor activity via synergistic mechanisms.

An anti-CD47 antibody-drug conjugate selectively binds tumor cells to deliver cytotoxic payloads.

Targeting O-acetylated-GD2 ganglioside with the 8B6 antibody eliminates resistant cancer stem cells while sparing healthy neurons lacking this antigen.

Phage display screens human antibody libraries to isolate fully human anti-EGFR variants, eliminating immune responses triggered by non-human structures.

Administering a CCR5 antagonist reduces inflammation and tissue remodeling in Th1 and Th2 mediated diseases.

Modified leukemic dendritic cells combined with anti-PD-L1 antibodies drive natural killer cell expansion through Fc receptor engagement.

Bispecific antibodies bind EGFR domain II and domain III to inhibit signaling in open conformations.